Feedback (LSE:FDBK) has agreed a contract extension with Queen Victoria Hospital to March 2027 and secured further development funding for its Bleepa platform, but says its cash runway extends only to the end of the first quarter of 2027 without additional Revenue or cash receipts.

What was announced

Feedback plc, the AIM-quoted clinical infrastructure specialist with LSE:FDBK, published a Business update on 29 October 2026. The company said the announcement contained inside information under UK market abuse rules.

Its customer QVH (Queen Victoria Hospital) has extended its existing contract to the end of March 2027, in a deal worth £127,000. The extension takes the contract to the end of the NHS financial year while national and regional discussions continue. Feedback said it had expected an annual renewal, but the invoice now runs only to the NHS year end.

QVH has also committed a further £249,000 for product development on the Bleepa platform. The money was awarded by the Surrey and Sussex Integrated Care Board (ICB). Feedback said the funding is aimed at improving how pathways are delivered and scaled, and could lead to some pathways being adopted more widely across the ICB in the coming months.

Cash position

The most significant financial disclosure is on cash. Feedback said that, without additional revenue or cash receipts, its cash runway is expected to extend to the end of Q1 2027. The update does not give a cash balance, revenue, annual recurring revenue, profit or cost figures, and it contains no formal financial guidance beyond the contract and funding amounts. The company stated that nothing in the announcement should be read as a profit forecast.

Chief executive Dr Tom Oakley said: "Despite a challenging trading environment we are encouraged by these emerging opportunities." He added that the opportunities could bring significant long-term value to shareholders and NHS customers.

NHS context and new opportunities

Feedback said NHS England now expects to start a wider commissioning programme covering clinical pathways and elective recovery in April 2027, and that it is positioning itself for this. An independent review of Bleepa at QVH found significant time and cost savings on the breathlessness and insomnia pathways, and noted potential for a wider rollout across ICBs.

Separately, one of the largest ICBs has approached Feedback about a multi-year elective transformation opportunity. The scope is still being negotiated and remains subject to contract terms, and Feedback said there is no certainty the project will go ahead. The likely structure is an initial paid pilot, with a clinical pathway going live across several providers around the end of the calendar year. This would then feed into a wider commissioning programme from April 2027. The work would be delivered with key delivery partners and, according to the company, could lead to similar opportunities with other ICBs. No value for the pilot or the wider programme has been disclosed.

Background

Bleepa is Feedback's collaboration platform for patient pathways. The company sells it on a software-as-a-service basis, which it says should give increasing revenue visibility as the customer base grows. The company cites the independent review of the QVH work as evidence of Bleepa's potential for wider rollout across other ICBs.

What to watch next

The key issues are whether the large ICB opportunity reaches a signed contract and paid pilot, how the NHS England commissioning programme develops ahead of April 2027, and how the company addresses its funding position given the runway disclosed to the end of Q1 2027. The announcement does not say whether any further fundraising is planned or under consideration. Feedback's nominated adviser and broker is Panmure Liberum.